Clinical Trials Logo

Clinical Trial Summary

This research is studying a drug called dupilumab to learn about its safety and its effect as a treatment for participants with dermal hypersensitivity reaction. This study will help better understand why and how dermal hypersensitivity reaction occurs and how dupilumab might help treat this condition.


Clinical Trial Description

Dermal hypersensitivity reaction is a skin rash that can happen as a reaction to a known trigger or it can happen for unknown reasons. Not a lot is known about why the rash occurs and what happens to the immune system to cause this rash. Dupilumab, a biologic drug that is given as an injection under the skin, may treat dermal hypersensitivity reaction. This study tries to better understand dermal hypersensitivity reaction and how the immune system responds to dupilumab. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06012448
Study type Interventional
Source University of Michigan
Contact Nicole Nechiporchik
Phone 734-936-7519
Email nnechipo@umich.edu
Status Recruiting
Phase Phase 4
Start date October 2, 2023
Completion date December 2025